Philips gains FDA approval for AI-powered Spectral CT Innovation in United States

THE NETHERLANDS—Royal Philips has received U.S. Food and Drug Administration 510(k) clearance for its Spectral CT Verida system, marking a significant milestone in bringing advanced medical imaging technology to American healthcare providers.

The move expands access to next-generation spectral CT capabilities that combine artificial intelligence with detector-based imaging to enhance diagnostic accuracy.

Cutting-Edge technology meets clinical efficiency

The Verida system represents a leap forward in CT imaging, incorporating Philips’ third-generation Nano-panel Precise dual-layer detector alongside an AI-driven deep learning reconstruction engine.

Together, these components work to reduce image noise and improve clarity across various clinical applications.

A key advantage lies in the system’s flexibility—clinicians can customize image de-noising parameters to match their specific preferences and diagnostic needs.

Dan Xu, Business Leader of CT at Philips, emphasized the importance of this development.

“With FDA clearance for Verida, we’re bringing the next evolution of spectral CT to more markets,” he stated.

By merging always-on spectral imaging with AI-powered reconstruction, the system enables clinicians to capture more diagnostic information with greater confidence, supporting quicker clinical decision-making while expanding CT’s role across multiple medical pathways.

Performance built for modern healthcare workflows

The Verida’s engineering focuses on practical clinical integration rather than disruptive changes to existing workflows.

The system maintains Philips’ industry-leading detector-based spectral imaging technology while introducing enhancements that streamline operations.

These improvements include a faster spectral result generation pipeline and upgraded computing infrastructure designed to boost both performance and usability.

The speed advantage is particularly notable.

Verida reconstructs 145 images per second, allowing complete examinations to appear on screens in under 30 seconds—twice as fast as previous generations.

This efficiency translates to a capacity of up to 270 exams daily, significantly boosting patient throughput.

Simultaneous data capture eliminates repeat scans

A fundamental feature distinguishes Verida from conventional CT systems: it captures both high- and low-energy data in a single acquisition.

This dual-capture approach means clinicians instantly access both conventional and spectral imaging results without requiring additional scans or workflow modifications.

The simultaneous availability of both data sets enhances tissue characterization and material differentiation, providing deeper clinical insights while eliminating unnecessary repeat imaging.

Broad clinical applications

The system is approved for diagnostic imaging across multiple specialties, including radiology, interventional radiology, and cardiology.

Oncology departments can utilize Verida for treatment preparation and radiation therapy planning.

The system accommodates patients of all ages and supports head, whole-body, cardiac, and vascular CT applications.

Additionally, Verida qualifies for low-dose CT lung cancer screening when performed according to established screening protocols.

Extended field-of-view imaging and respiratory-correlated scanning—known as 4DCT—are specifically designed for treatment preparation and radiation therapy planning applications.